Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22844069 | 0.83 | L3MBTL1 (0.37) | BRD4CREBBPEGLN1L3MBTL1 | |
| SCHEMBL21333288 | 0.79 | RXFP1 (0.39) | BRD4CREBBPSMN1; SMN2RXFP1TLR7 | |
| SCHEMBL9280321 | 0.77 | RNASEH1 (0.48) | RNASEH1CYP1A2SMN1; SMN2RXFP1DRD2 | |
| SCHEMBL20477374 | 0.76 | RNASEH1 (0.47) | RNASEH1CYP1A2SMN1; SMN2RXFP1DRD2 | |
| SCHEMBL22079307 | 0.74 | RNASEH1 (0.57) | RNASEH1CYP1A2SMN1; SMN2RXFP1L3MBTL1 | |
| SCHEMBL21332761 | 0.74 | RXFP1 (0.39) | CYP1A2SMN1; SMN2RXFP1TLR7ACSL1 | |
| SCHEMBL21333059 | 0.73 | LTA4H (0.51) | SMN1; SMN2RXFP1TLR7L3MBTL1 | |
| SCHEMBL20477364 | 0.72 | RNASEH1 (0.44) | RNASEH1CYP1A2SMN1; SMN2RXFP1DRD2 | |
| SCHEMBL20477354 | 0.71 | ADCY10 (0.43) | RNASEH1RXFP1DRD2TBXA2RPLA2G2A | |
| SCHEMBL6491001 | 0.70 | PARP1 (0.52) | RNASEH1CYP1A2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | CORNELL UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3762377-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | Cook, Timothy, H. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| WO-2019173790-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | HLA TIMOTHY (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | PTGER1, LOXL1, COL1A1 | RNASEH1 1523/4885BRD4 2394/4885CREBBP 2747/4885 |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | PTGER1, LOXL1, COL1A1 | RNASEH1 1523/4885BRD4 2394/4885CREBBP 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.